Shares in Novogen Limited (ASX:NRT, NASDAQ:NVGN) closed more than 38 per cent stronger on the ASX yesterday after revealing promising study results.
The dual-listed drug developer says US studies have confirmed one of its lead candidate products TRXE-009 kills brain cancer stem cells.
Novogen believes the product’s potent killing of highly resistant adult and pediatric brain cells presents an opportunity to effect the prevention of the recurrence of brain cancer.
CEO Dr Graham Kelly says the TRXE-009 drug has been a drug development success story and has so far ticked every box asked of it.
Novogen reported a net loss of $2.43 million in the first half of the 2015 financial year.
